Results 141 to 150 of about 32,499 (205)

Challenges with drug management of children and adolescents living with human immunodeficiency virus on antiretroviral therapy: A narrative review. [PDF]

Afr J Prim Health Care Fam Med
Mthethwa PP, Naidoo P, Taylor M.
europepmc   +1 more source

A Priori Design, Combinatorial Synthesis, and Assessment of an Antipackaging Peptide Against Human Immunodeficiency Virus 1: Functional Role of Unnatural Trp Mimetics and Serendipitous Discovery of a Protease Inhibitor. [PDF]

ChemMedChem
Immel JR, Chen PH, McDonald P, Roy A, Johnson D, Bloom S.   +5 more
europepmc   +1 more source

Pattern Recognition Algorithms in Pharmacogenomics and Drug Repurposing-Case Study: Ribavirin and Lopinavir. [PDF]

Pharmaceuticals (Basel)
Calvo H, Islas-Díaz D, Hernández-Laureano E.   +2 more
europepmc   +1 more source

Effect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africa

Brown JA, Sookrajh Y, Mtila L, Lushaba N, Hlabisa M, van der Molen JS, Tlhaku K, Nkosi M, Ngwenya T, Khubone T, Mahomed S, Chammartin F, Archary M, Garrett N, Lewis L, Dorward J.   +15 more
europepmc   +1 more source

Early outcomes of South African children with persistent viral non-suppression following switch to dolutegravir-based antiretroviral therapy. [PDF]

South Afr J HIV Med
Guerrini M, Maré M, Hulsman C, Greybe L, Lishman J, Edson C, Hisham T, Frigati L, Rabie H.   +8 more
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. [PDF]

AIDS
Blankenberger J, Devendra A, Bakaya M, Lee T, Steffy TLF, Makhesi T, Gilbride CJ, Belus JM, Thahane L, Tschumi N, Marake NB, Tarumbiswa T, Huber R, Chammartin F, Labhardt ND, Brown JA.   +15 more
europepmc   +1 more source

Pharmaceutical Sovereignty as HIV Justice: Colombia's Dolutegravir License and the Future of ART Access in Latin America. [PDF]

J Int AIDS Soc
Cifuentes LM, Brisson JB, Zea A, David PM.   +3 more
europepmc   +1 more source

Timeliness of switching to second-line antiretroviral therapy following virologic failure in Dar es Salaam, Tanzania. [PDF]

BMC Res Notes
Thadeo MH, Bwire GM.
europepmc   +1 more source

Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function. [PDF]

Nat Commun
Cui M, Liu X, Lan TH, Wang T, Nonomura T, McKee B, Wang R, Huang Y, Zhou Y.   +8 more
europepmc   +1 more source